Document is current

Any future updates will be listed below

Correction to: A Cost‑effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China

Crossref DOI link: https://doi.org/10.1007/s40261-023-01269-4

Published Online: 2023-04-28

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark